Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
What does it do?
Zimmer Biomet makes the metal and plastic parts that go inside your body when a surgeon replaces your knee or hip. Think of them as the manufacturer behind the artificial joints that let millions of people walk again after arthritis or injury destroys their natural ones. They also make smaller products like shoulder implants, ankle hardware, and the tools surgeons use to fix torn ligaments. If someone you know has had a knee replacement, there is a real chance Zimmer Biomet made the implant.
The global population is aging fast, and worn-out joints are one of the biggest reasons older adults lose mobility — demand for knee and hip replacements is expected to keep climbing for decades. Zimmer Biomet is one of only a handful of companies with the scale, surgeon relationships, and regulatory approvals to supply hospitals worldwide, making it a dominant player in a market that is hard to disrupt. At a $17 billion market cap, investors are watching whether the company can convert that structural tailwind into consistent profit growth.
How does it make money?
Zimmer Biomet generated $8.2 billion in revenue last year, up from $7.7 billion the prior year — a roughly 6.5% increase. The bulk of that money comes from selling knee and hip replacement systems directly to hospitals and surgical centers, which pay per procedure. A second, faster-growing segment called S.E.T. covers sports medicine, shoulder, ankle, and trauma products. The company sells both the implants themselves and the specialized surgical instruments needed to install them, creating a recurring relationship with surgeons and hospitals over time.
Why do investors care?
The investment case rests on a simple demographic bet: as Baby Boomers age and obesity rates rise, the number of joint replacement surgeries is projected to grow significantly through the 2030s. Zimmer Biomet is also pushing into robotics-assisted surgery with its ROSA robotic platform, which could deepen its grip on hospital operating rooms by making surgeons more reliant on its full ecosystem of tools and implants. For the thesis to work, the company needs to keep growing revenue, expand its profit margins, and successfully compete against rivals like Stryker and Johnson & Johnson who are chasing the same hospitals.
Deep Dive
MemberA full investor briefing on Zimmer Biomet Holdings, Inc. — history, leadership, risks, and outlook.